Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (18369)	1/10/2000 11:06:00 AM
From: DlphcOracl	Read Replies (1) \| Respond to of 57584

Aurora Biosciences (ABSC) announces the acceptance of its screening subsystem Screen Development Stage ("SDS") by Merck. This is a standalone addition to its Ultrahigh Throughput Screening System (UHTSS) platform. ABSC is an enabling technology in the biotech sector. It provides proprietary screening systems and services to other biotech and pharmaceutical companies to help them develop drugs more efficiently. It is a great way to play the genomics revolution without the risk that other biotechs have with drug development and FDA approval. Nice review of this cutting-edge company is at the following link: fnews.yahoo.com. Compared to the genomics high-flyers like HSGI, it a still very reasonably priced at $29.